Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography–tandem mass spectrometry following automated solid-phase extraction
- 15 March 2003
- journal article
- Published by Elsevier
- Vol. 788 (2) , 377-386
- https://doi.org/10.1016/s1570-0232(03)00063-1
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Hollow‐Fiber Unit Evaluation of a New Human Immunodeficiency Virus Type 1 Protease Inhibitor, BMS‐232632, for Determination of the Linked Pharmacodynamic VariableThe Journal of Infectious Diseases, 2001
- In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632Antimicrobial Agents and Chemotherapy, 2000
- Quantification of the anti‐HIV drug saquinavir by high‐speed on‐line high‐performance liquid chromatography/tandem mass spectrometryJournal of Mass Spectrometry, 1995
- Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studiesEuropean Journal of Drug Metabolism and Pharmacokinetics, 1991